Skip to main content
SpringerLink
Log in

CTLA4-Antikörper in der Therapie des metastasierten Melanoms

Treatment of metastatic melanoma with CTLA4 antibodies

  • Gehört-Gelesen-Nachgefragt
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med [Epub ahead of print]

  2. Harmankaya K, Erasim C, Koelblinger C et al (2010) Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol [Epub ahead of print]

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie, Universität Regensburg, Franz-Josef-Strauss-Allee 11, 93053, Regensburg, Deutschland

    C. Hafner

Authors
  1. C. Hafner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Hafner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hafner, C. CTLA4-Antikörper in der Therapie des metastasierten Melanoms. Hautarzt 61, 808–810 (2010). https://doi.org/10.1007/s00105-010-2033-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-010-2033-5

Search

Navigation